{
    "clinical_study": {
        "@rank": "62215", 
        "arm_group": {
            "arm_group_label": "LDFWART + Chemo", 
            "arm_group_type": "Experimental", 
            "description": "This study has 6 treatment cycles given at 3 weeks intervals \u00b1 3 days. A cycle is defined as 1 treatment of morning chemotherapy and afternoon LDF-WART. The first day of the first treatment is designated \"study day 1\"."
        }, 
        "brief_summary": {
            "textblock": "The ultimate clinical aim of this proposed phase I trial is to evaluate  the toxicity and\n      determine the recommended phase II dose of combining the effect of  LDFWART following\n      administration of Carboplatin and docetaxel for 6 cycles in patients with recurrent\n      platinum-sensitive and - resistant ovarian cancer."
        }, 
        "brief_title": "Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART) With Carboplatin and Docetaxel in Patients With Recurrent Ovarian Cancer", 
        "condition": [
            "Ovarian Cancer", 
            "Ovarian Carcinoma", 
            "Recurrent Ovarian Cancer", 
            "Recurrent Ovarian Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have recurrent adenocarcinoma following first-line chemotherapy for\n             metastatic disease.  There is no limit on prior number of chemotherapy regimens.\n             Patients who have received prior systemic docetaxel and platinum-based chemotherapy\n             are eligible\n\n               -  Patients must have > 1cm measurable disease on imaging studies independent of\n                  patients having an optional surgical salvage procedure.\n\n          -  Patients must have a life expectancy of at least 6 months.\n\n          -  Patients must have Karnofsky performance status (see Appendix F) of > 60 or\n             Gynecology Oncology (GOG) performance status of < 2 (see www.GOG.org website).\n\n          -  Age 18 - 80 years old\n\n          -  Patients must have an adequate bone marrow, renal, and hepatic function:\n\n               -  WBC: > 3,000 /mcl\n\n               -  ANC: > 1,500 /mcl\n\n               -  Platelets: > 100,000 /mcl\n\n               -  Creatinine: < 2.0 mg/dcl\n\n               -  Bilirubin: < 1.5x institutional normal value\n\n               -  LDH, GGT, SGPT (ALT), SGOT (AST), and ALK Phos:< 3x institutional normal value.\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          -  Patients who have received prior radiotherapy to the chest, whole abdomen, or lower\n             extremities above the knees.\n\n          -  Patients who have received prior radiation therapy to the head, neck, or lower\n             extremities below the knees if greater than 3 years prior to study entry.\n\n          -  Evidence of extra-abdominal extension of disease (such as groin nodes, lung,\n             supraclavicular nodes, and pleural fluid).\n\n          -  Patients may not be receiving any other investigational agents within 4 weeks\n             preceding the start of study treatment) or chemotherapy for at least 3 weeks\n             preceding the start of study treatment.\n\n          -  Patients who have been diagnosed with another prior malignant tumor within 3 years of\n             study entry, excluding non-melanoma skin cancer and carcinoma in situ of the cervix.\n\n          -  Patients with prior history of a severe hypersensitivity reaction to paclitaxel\n             (polysorbate 80-Cremophor) or carboplatin.\n\n          -  Patients with current history of uncontrolled hypertension, angina pectoris, heart\n             failure, cardiac dysrhythmias, pericardial disease, cardiomyopathy, or active\n             infection.\n\n          -  Presence of any medical condition that in the opinion of the investigator deems the\n             patient unable to participate.\n\n          -  Females of child-bearing potential. It is expected that ovarian cancer patients would\n             have had a hysterectomy and/or oophorectomy as part of the original standard of care.\n\n          -  Patients that are < 18 yrs. of age or > 80 yrs. of age"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083536", 
            "org_study_id": "UMIAMI-20110671"
        }, 
        "intervention": [
            {
                "arm_group_label": "LDFWART + Chemo", 
                "description": "A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel and Carboplatin for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).", 
                "intervention_name": "Low  Dose Fractionated Whole Abdominal Radiation Therapy", 
                "intervention_type": "Radiation", 
                "other_name": "LDFWART"
            }, 
            {
                "arm_group_label": "LDFWART + Chemo", 
                "description": "Chemotherapy will consist of 6 cycles of Docetaxel and Carboplatin. Each cycle will follow standard of care and will be scheduled every 3 weeks \u00b1 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle,  chemotherapy will consist of Docetaxel 60 mg/m\u00b2 infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration) followed by Carboplatin AUC 5 IV over 30 - 60 minutes.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LDFWART + Chemo", 
                "description": "Chemotherapy will consist of 6 cycles of Docetaxel and Carboplatin. Each cycle will follow standard of care and will be scheduled every 3 weeks \u00b1 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle,  chemotherapy will consist of Docetaxel 60 mg/m\u00b2 infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration) followed by Carboplatin AUC 5 IV over 30 - 60 minutes.", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Low Dose Fractionated Whole Abdominal Radiation Therapy", 
            "LDFWART", 
            "Carboplatin", 
            "Docetaxel", 
            "Ovarian Cancer", 
            "Ovarian Carcinoma"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "contact": {
                "email": "sylvester@emergingmed.com", 
                "last_name": "University of Miami Sylvester Comprehensive Cancer Center", 
                "phone": "866-574-5124"
            }, 
            "contact_backup": {
                "email": "awolfson@med.miami.edu", 
                "last_name": "Aaron H Wolfson, MD", 
                "phone": "305-243-4210"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "University of Miami Sylvester Comprehensive Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Joseph Lucci III, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lorraine Portelance, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew Pearson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Fiona Simpkins, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rita-Ann Monde, Ph.D", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study Using Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART) As A Carboplatin & Docetaxel Chemo-Potentiator for Patients With Recurrent Ovarian Carcinoma", 
        "overall_official": [
            {
                "affiliation": "University of Miami Sylvester Comprehensive Cancer Center", 
                "last_name": "Aaron Wolfson, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Miami Sylvester Comprehensive Cancer Center", 
                "last_name": "Aaron H Wolfson, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of subjects experiencing adverse events after receiving LDFWART + Chemo study therapy. To determine the safety and recommended phase II dose of low-dose whole abdominal radiation therapy (LDFWART) when used in conjunction with 6 cycles of carboplatin and docetaxel  chemotherapy for patients with recurrent carcinoma of the ovary (without extra-abdominal extent of disease).", 
            "measure": "Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083536"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of subjects experiencing complete response (CR) or partial response (PR) according to RECIST Criteria Version 1.1", 
                "measure": "Number of Subjects Experiencing Complete or Partial Response to Protocol Therapy", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Observed length of life from start of treatment to cause of death", 
                "measure": "The rate of Overall Survival in subjects receiving protocol therapy", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Length of time from start of treatment to the time of documented disease progression in study subjects", 
                "measure": "The rate of Progression-Free Survival in subjects receiving protocol therapy.", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "University of Miami Sylvester Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Miami Sylvester Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}